Who are Assigned pulmonary hypertension medication's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tracleer®, "Nefecon®","Ambrisentan", EFI/ACT-385781A, Macitentan/Tadalafil FDC, FDC macitentan/tadalafil, SCH-58235.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/assigned-pulmonary-hypertension-medication.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Assigned pulmonary hypertension medication — Competitive Intelligence Brief

Assigned pulmonary hypertension medication (Assigned pulmonary hypertension medication) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 2 Endothelin receptor antagonist Endothelin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Assigned pulmonary hypertension medication (Assigned pulmonary hypertension medication) — Bayer. This drug works by inhibiting the action of endothelin-1, a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Assigned pulmonary hypertension medication TARGET	Assigned pulmonary hypertension medication	Bayer	phase 2	Endothelin receptor antagonist	Endothelin receptor
Tracleer®	Tracleer®	Actelion	marketed	Endothelin receptor antagonist	Endothelin receptor A (ETA) and Endothelin receptor B (ETB)
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)
EFI/ACT-385781A	EFI/ACT-385781A	Actelion	phase 3	Selective endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
Macitentan/Tadalafil FDC	Macitentan/Tadalafil FDC	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5
FDC macitentan/tadalafil	FDC macitentan/tadalafil	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5
SCH-58235	SCH-58235	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Endothelin receptor antagonist	Endothelin receptor (ETA/ETB)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Assigned pulmonary hypertension medication — Competitive Intelligence Brief. https://druglandscape.com/ci/assigned-pulmonary-hypertension-medication. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab